88 results about "ISONIAZID/PYRIDOXINE" patented technology

The invention provides a medicament for treating pulmonary tuberculosis. Adenophora root, Tuber of Dwarf Lilyturf, asparagi radix, rehmanniae radix, Rehmannia Glutinosa, stemona, tendril-leaved fritillary bulb, donkey-hide gelatin, pseudo-ginseng, Poria cocos, Chinese yam, polyghace seche, lily, bletilla striata, hairyvein agrimony, cortex lycii, isoniazid and vitamin B6 are mixed uniformly, and crushed into a medicinal powder of 80-120 mesh; and the medicinal powder is disinfected and filled into capsules to obtain the capsule product. The medicament is composed of traditional Chinese medicines and Western medicines, has efficacies of resisting tuberculosis, disinfesting, supporting right, securing the root, nourishing yin, reliving cough, reducing phlegm and stopping bleeding, and can play fast curative effect without side effect on treatment of pulmonary tuberculosis.

The invention discloses isoniazid indicated in formula (I), which has a new purpose of being used as histone deacetylase inhibitor. The isoniazid is used to prepare medicine to prevent and/or treat a plurality of diseases related to histone deacetylase.

The present invention belongs to the field of chemically synthesized medicine and its preparation process. The medicine of the present invention is synthesized with amantadine, moroxydine, 5-Fu (5-Fc), isoniazid and other clinical medicine and polyoxometallate, and through self-assembling. The said polyoxometallate includes heteropoly acid salts of Keggin type with chemical expression XM12O40n-, Dowson type X2M18O62n- and of chemical expression LnW10O36n-. The combined use of said medicines and polyoxometallate has obvious curative effect on intractable streptococcus pneumoniae infection.

This invention relates to a test for detecting a Mycobacterium tuberculosis (tuberculosis or TB) infection in a patient or subject, specifically a diagnostic test, including a breath test, whereby patients are provided a small dose of an isotopically labeled TB drug, Isoniazid (INH) orally or directly to the lungs of the patient or subject. If TB is present, a TB enzyme mycobacterial peroxidase KatG oxidizes the INH; and KatG specific metabolites, in particular, isotopically labeled nitric oxide (NO), nitrites, nitrates, carbon monoxide (CO) or carbon dioxide converted from carbon monoxide of INH cleavage are measured. Other embodiments relate to a diagnostic breath test for detecting TB utilizing isotopically labeled urea (preferably, carbon-13 labeled urea), alone or in combination with isotopically labeled isoniazid (preferably, nitrogen-15 labeled isoniazid), wherein M. tuberculosis organism, if present in the patient or subject's lungs (or other tissues), will metabolize the isotopically labeled urea to isotopically labeled carbon dioxide (CO₂) such that a determination of the residence of M. tuberculosis, including residence of an isoniazid resistant strain of M. tuberculosis, may be made.

The invention discloses a preparation method of isoniazid. The method comprises the following steps: 1) performing esterification reaction to isonicotinic acid, alcohol and acylating reagent to obtain isonicotinic acid ester; 2) performing condensation reaction to isonicotinic acid ester and hydrazine hydrate and performing post-treatment to reaction liquid to obtain isoniazid finished products. The isoniazid is prepared firstly through esterification of isonicotinic acid and alcohol and then condensation of the obtained ester and hydrazine hydrate. The method can well control the content of impurities in the target product isoniazid, high-purity isoniazid can be obtained, the purity is above 99.9 percent and the content of individual impurity is smaller than 0.10 percent. The method is simple to operate, is easy to control and is applicable to industrial operation. In addition, by using recovered isonicotinic acid to prepare isoniazid, the cyclic utilization of resources can be realized, the waste emission is reduced, the cost is reduced and the method is very suitable for industrial production.

The invention discloses a preparation method of isoniazid para-aminosalicylate. The preparation method comprises that a sodium para-aminosalicylate solution is added with an acid and then is extracted by an organic solvent and isoniazid is added into the extract to produce a desired product. The isoniazid para-aminosalicylate product prepared by the preparation method has isoniazid para-aminosalicylate purity above 98%. Through the preparation method, a yield of 90 to 98% is obtained. The preparation method adopts simple and environmentally friendly processes, realizes recycle of an extraction solvent and saves greatly costs.

A pharmaceutical composition for treating tuberculotic diseases with no side effect/low side effect is provided by the present invention, which pharmaceutically effective amount of one or more compounds chosen from isoniazid, rifampin, pyrazinamide and ethambutol, and pharmaceutically effective amount of substances which can reduce the side effect of the antituberculosis agents.

The invention is a divisional application of 200610113436.7. The invention discloses novel purpose of isoniazid shown as a formula (I) as histone deacetylases inhibitor and application of isoniazid to preparation of medicaments for preventing and / or treating a plurality of diseases correlative to histone deacetylases.

The invention relates to a preparation method of isoniazid para-aminosalicylate. The preparation method of isoniazid para-aminosalicylate comprises the following steps: (1) respectively weighting water and an organic solvent, mixing, adding para-aminosalicylic acid and isoniazid to a solvent of the water and the organic solvent, heating and stirring; (2) cooling and growing grains, and filtering to obtain isoniazid para-aminosalicylate, wherein the organic solvent is an organic ester with the carbon number of less than or equal to 6. By using the preparation method, the preparation of isoniazid para-aminosalicylate is realized at low cost and high efficiency in a water and ester two-phase solvent system under a simple, convenient and feasible technological condition. The content of isoniazid para-aminosalicylate prepared by the method is higher than 99%. Isoniazid para-aminosalicylate has good appearance crystal form, standard color and luster and good stability. The preparation method has the advantages of few reaction operating units, simple technological process, short time consumption, low production cost, environmental friendliness, simple operation and easiness for control on the implementation process and is suitable for the industrial production of isoniazid para-aminosalicylate.

The invention discloses a method for simultaneously detecting five anti-tuberculosis drugs (including rifampin, rifabutin, Pyrazinamide, ethambutol and isoniazid) in blood plasma via a UPLC-MS/MS method. Blank blood plasma is weighed precisely, and added with standard working solutions mixed with a series of standard substances, standard working solutions of isotope internal standards in one to one correspondence are added, pre-treatment is carried out in a protein precipitation method, the UPLC-MS/MS method is used for analysis, chromatograms of different samples are obtained, and a standardcurve is established by taking the ratio of an object to be measured and the corresponding internal standard peak area as the abscissa and the concentration of the object to be measured as the ordinate; and blood plasma to be measured is weighed precisely, the standard working solutions of isotope internal standards in one to one correspondence are added, pre-treatment is carried out in the protein precipitation method, the UPLC-MS/MS method is used for analysis, chromatograms of different samples are obtained, and the concentration of the blood plasma sample is calculated by using the standard curve. The method is simple and rapid in operation and high in sensitivity, accuracy and precision, the matrix effect is low, and can satisfy requirements for monitoring the drug concentration of five anti-tuberculosis drugs in clinical application.

The present invention discloses one kind of Chinese medicine powder for treating tuberculosis and its treating method via combination with Western medicines. The Chinese medicine powder consists of bletilla tuber, notoginseng, gallnut and pangolin scales, and is orally taken together with Western medicines isoniazid, ethambutol, metronidazole and vitamin B6. It is taken with pork stomach and lung soup or pork trotter soup. It has high curative effect, short treatment period, and other advantages, and may be industrial produced.

The invention relates to a rifamycin-isoniazide hybrid drug and a preparation method thereof. The rifamycin-isoniazide hybrid drug is prepared according to the preparation method which comprises the following steps: acidizing rifamycin sodium and then generating cyclisation with N,N-dihydroxymethyl tertbutylamine, thereby compounding oxazine rifamycin, and then performing condensation reaction on the oxazine rifamycin, piperazine and isoniazide, thereby acquiring the rifamycin-isoniazide hybrid drug. The rifamycin-isoniazide hybrid drug prepared according to the invention is stable in vitro, is difficult to degrade, is free from biological activity and can be dosed at multiple target points. The hybrid drug has higher biological activity, sterilizing effect equivalent to that of rifampicin and wide development prospect.

Nicotinamides and isonicotinamides, used in the preparation of anti-TB drugs i.e. isoniazid and as an intermediate of vitamin B₁₂ are prepared from cyanopyridines and nicotinamides. Catalysts useful for the preparation of nicotinamide and isonicotinamide.

The invention relates to a compound isoniazid tablet used for treating tuberculosis, which comprises isoniazid and vitamin B6, wherein the isoniazid and the vitamin B6 are mixed together and prepared into tablets when preparing the compound isoniazid tablet. Patients with stomach upset for taking the isoniazid can directly take the compound isoniazid tablet to achieve the function of treatment without having any stomach upset, and the invention lays a good foundation for treating the tuberculosis because of being more accepted by patients for reduced total amount of medicines taken.

A both fast-release and slow-release compound medicine for preventing and treating tuberculosis (TB) is prepared from rifampin, isoniazid in the ratio of 2:1, and the pharmacologically acceptable auxiliary consisting of skeleton material and disintegrant. Its preparing process is also disclosed.

The invention discloses a compound preparation containing rifampicin isoniazid and a preparation method thereof. The compound preparation containing rifampicin and isoniazid of the present invention is a double-layered chip containing rifampicin in a chip and an outer layer containing isoniazid and pyrazinamide. The preparation of the invention not only greatly reduces the polymer (3-methylrifamycin SV isoniazone) produced by rifampicin and isoniazid, but also statistical analysis and bioequivalence verification show that isoniazid, The above pharmacokinetic parameters of rifampicin and pyrazinamide were not significantly different between the two tablets (p>0.05), and the two tablets were bioequivalent.